Vnitr Lek 2012, 58(3):202-207

Oxidative stress in kidney disease patients

J. Vostálová1, A. Galandáková1,*, P. Štrebl2, J. Zadražil2, M. Kajabová3, P. Schneiderka3
1 Ústav lékařské chemie a biochemie Lékařské fakulty UP Olomouc, přednostka prof. RNDr. Jitka Ulrichová, CSc.
2 III. interní nefrologická, revmatologická a endokrinologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.
3 Oddělení klinické biochemie a imunogenetiky FN Olomouc, vedoucí oddělení doc. RNDr. Tomáš Adam, Ph.D.

Patients with chronic kidney disease are exposed to oxidative stress (OS) that contributes to deterioration of health. Decrease in renal excretory capacity contributes to the accumulation of pro-oxidative substances that are detrimental not only to kidney but to the whole organism including the cardiovascular system. Components of antioxidant system play an important role in the elimination of the OS. The monitoring of antioxidant levels and products of oxidative damage in these patients and the correct interpretation of relationship between these markers and the function of kidney and other organs may contribute to the more effective treatment and health improvement of the patients.

Keywords: reactive oxygen and nitrogen species; antioxidants; kidney; dialysis; transplantation; immunosuppressives

Received: May 13, 2011; Accepted: October 10, 2011; Published: March 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vostálová J, Galandáková A, Štrebl P, Zadražil J, Kajabová M, Schneiderka P. Oxidative stress in kidney disease patients. Vnitr Lek. 2012;58(3):202-207.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906. Go to original source... Go to PubMed...
    2. Dusilová Sulková S. Klinický význam cévního postižení u diabetiků s onemocněním ledvin - pohled neurologa. Vnitř Lék 2010; 56: 351-355. Go to PubMed...
    3. Zemánek D. Ischemická choroba srdeční a onemocnění ledvin. Kardiol Rev 2005; 4: 191-194.
    4. Yeo FE, Villines TC, Bucci JR et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 2004; 11: 116-133. Go to original source... Go to PubMed...
    5. Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 2009; 5: 287-296. Go to original source... Go to PubMed...
    6. Himmelfarb J. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 2005; 23: 319-330. Go to original source... Go to PubMed...
    7. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-1828. Go to original source...
    8. Babior BM. Superoxide: a two-edged sword. Braz J Med Biol Res 1997; 30: 141-155. Go to original source... Go to PubMed...
    9. Darley-Usmar V, Halliwell B. Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Pharm Res 1996; 13: 649-662. Go to original source... Go to PubMed...
    10. Racek J. Oxidační stres a možnosti jeho ovlivnění. Praha: Galén 2003.
    11. DeLeo FR, Renee J, McCormick S et al. Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Incest 1998; 101: 455-463. Go to original source... Go to PubMed...
    12. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636-643. Go to original source... Go to PubMed...
    13. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-F671. Go to original source... Go to PubMed...
    14. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-295. Go to original source... Go to PubMed...
    15. Alhamdani MS, Al-Kassir AH, Jaleel NA et al. Elevated levels of alkanals, alkenals and 4-HO-alkenals in plasma of hemodialysis patients. Am J Nephrol 2006; 26: 299-303. Go to original source... Go to PubMed...
    16. Morena M, Delbosc S, Dupuy AM et al. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005; 9: 37-46. Go to original source... Go to PubMed...
    17. Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924. Go to original source...
    18. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280. Go to original source... Go to PubMed...
    19. Zadák Z, Hyspler R, Tichá A et al. Antioxidants and vitamins in clinical conditions. Phy-siol Res 2009; 58: S13-S17. Go to original source...
    20. Štípek S et al. Antioxidanty a volné radikály ve zdraví a v nemoci. Praha: Grada 2000.
    21. Kalousová M, Zima T, Tesař V et al. Advanced glycoxidation end products in chronic diseases - clinical chemistry and genetic background. Mutat Res 2005; 579: 37-46. Go to original source... Go to PubMed...
    22. Descamps-Latscha B, Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis. Nephrologie 2003; 24: 377-379. Go to PubMed...
    23. Capeillere-Blandin C, Deleveau T, Descamps-Latscha B. Structural modification of human β2-microglobulin treated with oxygen-derived radicals. Biochem J 1991; 277: 175-182. Go to original source... Go to PubMed...
    24. Mitrogianni Z, Barbouti A, Galaris D et al. Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract 2009; 113: 234-240. Go to original source... Go to PubMed...
    25. Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79: 914-919. Go to original source... Go to PubMed...
    26. Pupim LB, Himmelfarb J, McMonagle E et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004; 65: 2371-2379. Go to original source... Go to PubMed...
    27. Marsche G, Frank S, Hrzenjak A et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009; 104: 750-757. Go to original source... Go to PubMed...
    28. Bertram C, Hass R. Cellular responses to reactive oxygen species-induced DNA damage and aging. Biol Chem 2008; 389: 211-220. Go to original source... Go to PubMed...
    29. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010; 38: 96-109. Go to original source... Go to PubMed...
    30. Valko M, Izakovic M, Mazur M et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004; 266: 37-56. Go to original source... Go to PubMed...
    31. Herman M, Ori Y, Chagnac A et al. Spontaneous DNA repair increases during hemodialysis. Nephron Clin Pract 2008; 108: c188-c193. Go to original source... Go to PubMed...
    32. Horoz M, Bolukbas FF, Bolukbas C et al. The association of circulating leptin level with peripheral DNA damage in hemodialysis subjects. Clin Biochem 2006; 39: 918-922. Go to original source... Go to PubMed...
    33. Kobras K, Schupp N, Nehrlich K et al. Relation between different treatment modalities and genomic damage of end-stage renal failure patients. Kidney Blood Press Res 2006; 29: 10-17. Go to original source... Go to PubMed...
    34. Stoyanova E, Sandoval SB, Zúñiga LA et al. Oxidative DNA damage in chronic renal failure patients. Nephrol Dial Transplant 2010; 25: 879-885. Go to original source... Go to PubMed...
    35. Racek J, Holeček V. Enzymy a volné radikály. Chem listy 1999; 93: 774-780.
    36. Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 1999; 32: 595-603. Go to original source... Go to PubMed...
    37. Tsuchikura S, Shoji T, Shimomura N et al. Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. BMC Nephrol 2010; 11: 7-13. Go to original source... Go to PubMed...
    38. Kanďár R, Záková P. Allantoin as a marker of oxidative stress in human erythrocytes. Clin Chem Lab Med 2008; 46: 1270-1274. Go to original source... Go to PubMed...
    39. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002; 30: 620-650. Go to original source... Go to PubMed...
    40. Sánchez-Lozada LG, Nakagawa T, Kang DH et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 2006; 15: 30-33. Go to original source... Go to PubMed...
    41. Lippi G, Montagnana M, Franchini M et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1-7. Go to original source... Go to PubMed...
    42. Puchades Montesa MJ, González Rico MA, Solís Salguero MA et al. Study of oxidative stress in advanced kidney disease. Nefrologia 2009; 29: 464-473. Go to PubMed...
    43. Romeu M, Nogues R, Marcas L et al. Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study. BMC Res Notes 2010; 3: 20-26. Go to original source... Go to PubMed...
    44. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59. Go to original source... Go to PubMed...
    45. Alhamdani MS. Impairment of glutathione biosynthetic pathway in uraemia and dialysis. Nephrol Dial Transplant 2005; 20: 124-128. Go to original source... Go to PubMed...
    46. Armstrong D. Advanced Protocols in Oxidative Stress I. New York: Springer 2008. Go to original source...
    47. Armstrong D. Advanced Protocols in Oxidative Stress II. New York: Springer 2010. Go to original source...
    48. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998; 44: 1309-1315. Go to original source...
    49. Wayner DD, Burton GW, Ingold KU et al. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett 1985; 187: 33-37. Go to original source... Go to PubMed...
    50. Kuchta A, Pacanis A, Kortas-Stempak B et al. Estimation of Oxidative Stress Markers in Chronic Kidney Disease. Kidney Blood Press Res 2010; 34: 12-19. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.